German and UK researchers cut time to sepsis diagnosis
Researchers from German Fraunhofer IGBI have used next-generation sequencing (NGS) to diagnosis sepsis from tiny amounts of microbial DNA in the blood.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1243 entries already.
Entries by Thomas Gabrielczyk
IMI launches 45m call for coronavirus emergency
/in News/by Thomas GabrielczykThe Innovative Medicines Initiative (IMI) has announced a 45m funding for the development of therapeutics and diagnostics to tackle coronavirus outbreaks.
Immunocore Ltd raises US$130m in Series B round
/in News/by Thomas GabrielczykWith the financing led by General Atlantic, the British company wants to expand a novel platform and advance its ImmTAX pipeline to the clinic.
Vitamin C may boost checkpoint inhibitor efficacy
/in News/by Thomas GabrielczykHigh amounts of injected vitamin C may delay the growth of many types of tumours and boost the anticancer power of immune checkpoint therapies, report Italian oncologists.
Roche grabs Bicycle Therapeutics platform
/in News/by Thomas GabrielczykRoche AGs has paid US$30m upfront in a potential US$1.7bn deal to get access to Bicycle Therapeutics plcs technology platform to target immune checkpoints.
Microglia inhibitor stops neuronal cell death after TBI
/in News/by Thomas GabrielczykResearchers at Trinity College in Dublin have demonstrated that resetting brain-specific immune cells improves traumatic brain injury (TBI) recovery.
Post-Brexit budget drives cuts in Horizon Europe
/in News/by Thomas GabrielczykNegotiations of the EU Council on the EU’s seven-year budget have failed, putting R&D funding at risk for significant cuts.
Royal DSM acquires Glycom A/S for 765m
/in News/by Thomas GabrielczykRoyal DSM NV has entered the growing market of human milk oligosaccharides (HMO) taking over the producer of recombinant 2-fucosyl lactose, Danish Glycom A/S.
Immatics Biotechnologies lands 1.1bn deal with GSK
/in News/by Thomas GabrielczykUS-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront.
KKR backs Belgian tech provider Univercells SA
/in News/by Thomas GabrielczykUnivercells S.A. cashes in up to 50m from the KKR subsidiary Gamma Bioscience to advance its gene and cell therapy manufacturing platform.